88138
document
Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts . Recombinant human granulocyte colony-stimulating factor ( rhG-CSF ) is effective in countering chemotherapy-induced neutropenia . However , serum rhG-CSF levels can not be maintained throughout the course of rhG-CSF therapy . The drop in serum rhG-CSF levels may vary with the duration of rhG-CSF administration or with the circulating neutrophil counts . We investigated the relationship between serum G-CSF levels and circulating neutrophil counts and the pharmacokinetics of rhG-CSF for patients with lung cancer who had been treated with myelosuppressive chemotherapy and then with subcutaneous rhG-CSF ( lenograstim , 2 micrograms per kg of body weight per day ) . Twelve patients were randomly assigned to four groups with different rhG-CSF therapy schedules . Serum G-CSF levels were measured by an enzyme immunoassay method . Serum G-CSF levels during the rhG-CSF therapy greatly exceeded endogenous G-CSF levels and were mainly due to the presence of exogenous rhG-CSF rather than increased levels of endogenous G-CSF . Despite the duration of rhG-CSF administration , serum G-CSF levels during rhG-CSF therapy were inversely correlated with circulating neutrophil counts ( r2 = 0.73 , P < 0.0001 ) . The value for the area under the concentration-time curve of rhG-CSF on the day of neutrophilia was lower than that on the day of neutropenia ( P < 0.05 ) . Our results suggest that the fall in serum G-CSF levels during rhG-CSF therapy may result from increased clearance and/or decreased absorption of rhG-CSF , two processes related to circulating neutrophil counts .
88139
Intervention_Pharmacological
recombinant human granulocyte colony-stimulating factor
88140
Intervention_Pharmacological
Recombinant human granulocyte colony-stimulating factor ( rhG-CSF )
88141
Intervention_Pharmacological
rhG-CSF
88142
Intervention_Pharmacological
rhG-CSF therapy .
88143
Intervention_Pharmacological
rhG-CSF
88144
Intervention_Pharmacological
rhG-CSF
88145
Intervention_Pharmacological
rhG-CSF
88146
Intervention_Pharmacological
rhG-CSF therapy schedules
88147
Intervention_Pharmacological
rhG-CSF therapy
88148
Intervention_Pharmacological
rhG-CSF
88149
Intervention_Pharmacological
rhG-CSF
88150
Intervention_Pharmacological
rhG-CSF therapy
88151
Intervention_Pharmacological
rhG-CSF
88152
Intervention_Pharmacological
rhG-CSF therapy
88153
Intervention_Pharmacological
rhG-CSF
88154
Outcome_Physical
recombinant human granulocyte colony-stimulating factor
88155
Outcome_Physical
serum rhG-CSF levels
88156
Outcome_Physical
serum rhG-CSF levels
88157
Outcome_Physical
serum G-CSF levels
88158
Outcome_Physical
circulating neutrophil counts
88159
Outcome_Physical
Serum G-CSF levels
88160
Outcome_Physical
Serum G-CSF levels
88161
Outcome_Physical
endogenous G-CSF levels
88162
Outcome_Physical
serum G-CSF levels
88163
Outcome_Physical
concentration-time curve
88164
Outcome_Physical
rhG-CSF
88165
Outcome_Physical
serum G-CSF levels
88166
Participant_Condition
patients with lung cancer who had been treated with myelosuppressive chemotherapy and then with subcutaneous rhG-CSF ( lenograstim , 2 micrograms per kg of body weight per day )
88167
Participant_Sample-size
Twelve